These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 27101282)

  • 1. Iron Localization and Infectious Disease in Chronic Kidney Disease Patients.
    Nakanishi T; Kuragano T; Nanami M; Hasuike Y
    Am J Nephrol; 2016; 43(4):237-44. PubMed ID: 27101282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Iron Balance and the Role of Hepcidin in Chronic Kidney Disease.
    Ganz T; Nemeth E
    Semin Nephrol; 2016 Mar; 36(2):87-93. PubMed ID: 27236128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of Hepcidin-25 in Chronic Kidney Disease: Anemia and Beyond.
    Ueda N; Takasawa K
    Curr Med Chem; 2017; 24(14):1417-1452. PubMed ID: 28302014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erythropoiesis-independent effects of iron in chronic kidney disease.
    Patino E; Akchurin O
    Pediatr Nephrol; 2022 Apr; 37(4):777-788. PubMed ID: 34244852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepcidin is a potential regulator of iron status in chronic kidney disease.
    Tsuchiya K; Nitta K
    Ther Apher Dial; 2013 Feb; 17(1):1-8. PubMed ID: 23379486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The pathogenesis of CKD complications; Attack of dysregulated iron and phosphate metabolism.
    Nakanishi T; Nanami M; Kuragano T
    Free Radic Biol Med; 2020 Sep; 157():55-62. PubMed ID: 31978539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal function in patients with non-dialysis chronic kidney disease receiving intravenous ferric carboxymaltose: an analysis of the randomized FIND-CKD trial.
    Macdougall IC; Bock AH; Carrera F; Eckardt KU; Gaillard C; Van Wyck D; Meier Y; Larroque S; Roger SD;
    BMC Nephrol; 2017 Jan; 18(1):24. PubMed ID: 28095881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Novel Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial.
    Brigandi RA; Johnson B; Oei C; Westerman M; Olbina G; de Zoysa J; Roger SD; Sahay M; Cross N; McMahon L; Guptha V; Smolyarchuk EA; Singh N; Russ SF; Kumar S;
    Am J Kidney Dis; 2016 Jun; 67(6):861-71. PubMed ID: 26827289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepcidin: an important iron metabolism regulator in chronic kidney disease.
    Antunes SA; Canziani ME
    J Bras Nefrol; 2016; 38(3):351-355. PubMed ID: 27737394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Whole-body iron transport and metabolism: Mechanistic, multi-scale model to improve treatment of anemia in chronic kidney disease.
    Sarkar J; Potdar AA; Saidel GM
    PLoS Comput Biol; 2018 Apr; 14(4):e1006060. PubMed ID: 29659573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The iron cycle in chronic kidney disease (CKD): from genetics and experimental models to CKD patients.
    Zumbrennen-Bullough K; Babitt JL
    Nephrol Dial Transplant; 2014 Feb; 29(2):263-73. PubMed ID: 24235084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anemia in chronic renal disease: evaluation of inflammatory activity on erythropoiesis and iron metabolism in patients not submitted to dialysis treatment.
    De Lima GA; Mazzali M; Gentil AF; Plotegher L; Grotto HZ
    Clin Lab; 2012; 58(7-8):695-704. PubMed ID: 22997970
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone marrow iron distribution, hepcidin, and ferroportin expression in renal anemia.
    Bârsan L; Stanciu A; Stancu S; Căpuşă C; Brătescu L; Mandache E; Radu E; Mircescu G
    Hematology; 2015 Oct; 20(9):543-52. PubMed ID: 25745821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum hepcidin-25 levels and anemia in non-dialysis chronic kidney disease patients: a cross-sectional study.
    Uehata T; Tomosugi N; Shoji T; Sakaguchi Y; Suzuki A; Kaneko T; Okada N; Yamamoto R; Nagasawa Y; Kato K; Isaka Y; Rakugi H; Tsubakihara Y
    Nephrol Dial Transplant; 2012 Mar; 27(3):1076-83. PubMed ID: 21799206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The struggle for iron - a metal at the host-pathogen interface.
    Nairz M; Schroll A; Sonnweber T; Weiss G
    Cell Microbiol; 2010 Dec; 12(12):1691-702. PubMed ID: 20964797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Iron deficiency in ND-CKD: from diagnosis to treatment].
    Liberti ME; Garofalo C; Sagliocca A; Borrelli S; Conte G; De Nicola L; Minutolo R
    G Ital Nefrol; 2017 Sep; 34(5):50-61. PubMed ID: 28963827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anemia management in cancer patients with chronic kidney disease.
    Deak AT; Troppan K; Rosenkranz AR
    Eur J Intern Med; 2016 Dec; 36():13-19. PubMed ID: 27640913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum hepcidin-25 levels predict the progression of renal anemia in patients with non-dialysis chronic kidney disease.
    Niihata K; Tomosugi N; Uehata T; Shoji T; Mitsumoto K; Shimizu M; Kawabata H; Sakaguchi Y; Suzuki A; Hayashi T; Okada N; Isaka Y; Rakugi H; Tsubakihara Y
    Nephrol Dial Transplant; 2012 Dec; 27(12):4378-85; discussion 4384-5. PubMed ID: 22833619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety Issues in Iron Treatment in CKD.
    Vaziri ND
    Semin Nephrol; 2016 Mar; 36(2):112-8. PubMed ID: 27236132
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.